Disclosure of Relevant Financial Relationships with Commercial Interests

USF Health endorses the standards of the ACCME and all applicable accrediting organizations that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

Author

José R. Arribas, MD

Research Director (HIV and Infectious Diseases)
Hospital La Paz. IdiPAZ.
Madrid, Spain

José R. Arribas, MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck Sharp & Dohme, and ViiV. Dr. Arribas disclosed in previous editions that he had received consulting fees from Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Tibotec, Tobira, and Pfizer; served as a member of the advisory boards for Abbott, Avexa, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Tibotec, and ViiV; had received funds for research support from Abbott, Gilead Sciences, Janssen-Cilag, and Merck Sharp & Dohme; and had received fees for non-CME/CE services from Bristol-Myers Squibb, Gilead Sciences, Janssen, Tibotec, and ViiV.

Editors in Chief

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Bionor, Gilead Sciences, GlaxoSmithKline, InnaVirVax, Janssen, Merck, Oncolys, Teva, ViiV, and ViroStatics; fees for non-CME/CE services from Merck; and funds for research support from Gilead Sciences. Dr. Kuritzkes disclosed in previous editions that he had received consulting fees from Bristol-Myers Squibb, Celera, and Tobira; fees for non-CME/CE services from ViiV; and funds for research support from Merck.

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
Associate Director, Clinical and Translational Research Center
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from EMD Serono, Gilead Sciences, Janssen, Merck, TRIO Health, and ViiV and has received funds for research support from Gilead Sciences, Janssen, and ViiV. Dr. Eron disclosed in previous editions that he had received consulting fees from AbbVie, Avexa, Bristol-Myers Squibb, Chimerix, Inhibitex, Kainos, Koronis, Myriad, Pfizer, Roche Molecular Systems, Tobira, Tibotec/Janssen, and Virco; had received funds for research support from AbbVie, Bristol-Myers Squibb, Merck, Panacos, TaiMed, and Tobira; had served on speaker bureaus for Bristol-Myers Squibb, Gilead Sciences, Roche, Tibotec, and Virco; and had served on the data and safety monitoring board for TaiMed and Vertex.

Section Editor

Eric S. Daar, MD

Chief , Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Teva, Theratechnologies, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV. Dr. Daar disclosed in previous editions that he had received funds for research support from Bristol-Myers Squibb and consulting fees from AbbVie.

Staff

Jennifer M. Blanchette, PhD

Managing Editor

Jennifer M. Blanchette, PhD, has nothing to disclose with regard to commercial interests.

Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has nothing to disclose with regard to commercial interests.

Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, MS, RVT, has disclosed that she has received fees for non-CME activities from Lilly and Merck.

Edward King, MA

Executive Vice President

Edward King, MA, has nothing to disclose with regard to commercial interests.

Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has nothing to disclose with regard to commercial interests.

USF Health OCPD staff members and the peer/content reviewers for this activity have no relevant financial relationships to disclose. Disclosures are on file at the USF Health Office of Continuing Professional Development.

Additional Disclosure Information

The following staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:

Kathleen E. Squires, MD, disclosed that she had served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; had served on advisory boards for marketing purposes for Gilead Sciences and Janssen; had served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Koronis, Pfizer, Schering-Plough, Tobira, and Tibotec; had received funds for research support from BioCryst, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis, Merck, Schering-Plough, Tibotec, and Vertex; and had received consulting fees from GlaxoSmithKline and Merck at the time she contributed to this module.

Kimberly Y. Smith, MD, MPH, disclosed that she had served on advisory boards and as a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and ViiV and had participated in speaker bureaus for GlaxoSmithKline and Merck at the time she contributed to this module.

Sheralee Connors, MA; Beth Cameron, PhD; Kerry Garza, PhD; Taryn O’Loughlin Gross, PhD; Kiran Mir-Hudgeons, PhD; Kevin Obholz, PhD; Heather Stieglitz, PhD; and Michael Westhafer, MD, had nothing to disclose with regard to commercial interests at the time they contributed to this module.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Unapproved Use Disclosure

USF Health requires CME faculty to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may/will discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

USF Health Privacy Policy

USF Health Office of Continuing Professional Development (OCPD) has created a privacy policy to demonstrate our commitment to guarding the privacy of our clients. The following statements disclose our practices on gathering and disseminating information for this web site. The OCPD has security measures in place to protect the loss, misuse, and alteration of the information under our control. The OCPD does not share or sell any individual’s contact information, financial information, or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

If you have any questions about this privacy policy, please contact USF Health OCPD, at cpdsupport@health.usf.edu.

Equal Opportunity

USF is an Equal Opportunity/ Equal Access/ Affirmative Action Institution.

Contact Information

If you have technical queries about using this site, please contact: techhelp@clinicaloptions.com.

If you have credit related queries, please contact: cpdsupport@health.usf.edu.

inPractice Hepatology current certification period
Release Date: January 1, 2019
Expiration Date: June 30, 2019

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with viral hepatitis.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of viral hepatitis.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support

This program is supported by educational grants from AbbVie and Gilead Sciences.


inPractice HIV current certification period
Release Date: November 1, 2018
Expiration Date: April 30, 2019

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support:

This program is supported by educational grants from Gilead Sciences, Janssen Therapeutics, and ViiV.


Physician Continuing Medical Education (for Point of Care CME activities)
USF University

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and inPractice Resources. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF

USF Health designates this internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 CreditTM .Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Credit (Point of Care CME)

inPractice offers physicians AMA PRA Category 1 CreditTM for participation in this individual Internet point-of-care activity. Physicians may claim 0.5 credits per search. To claim point-of-care (PoC) CME credit through inPractice, eligible physicians must complete the following steps:

  1. Register online at http://www.inpractice.com
  2. Execute a search or submit a clinical question
  3. Review the applicable clinical sources
  4. Click the "Claim CME Credit" button at the top right corner of the content you have viewed
  5. Complete the simple evaluation questions addressing clinical application of learnings from the sources you have consulted

After submitting the evaluation, you will be presented with your online CME certificate as a pdf file. Records of all CME activities completed can be found on the "My CME" page.